CL2021001722A1 - Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer - Google Patents

Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer

Info

Publication number
CL2021001722A1
CL2021001722A1 CL2021001722A CL2021001722A CL2021001722A1 CL 2021001722 A1 CL2021001722 A1 CL 2021001722A1 CL 2021001722 A CL2021001722 A CL 2021001722A CL 2021001722 A CL2021001722 A CL 2021001722A CL 2021001722 A1 CL2021001722 A1 CL 2021001722A1
Authority
CL
Chile
Prior art keywords
methods
heterobicyclic
aza
cancer treatment
mat2a
Prior art date
Application number
CL2021001722A
Other languages
English (en)
Inventor
Zenon D Konteatis
Mingzong Li
Samuel K Reznik
Zhihua Sui
Jeremy M Travins
Original Assignee
Les Laboratoires Servier Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier Sas filed Critical Les Laboratoires Servier Sas
Publication of CL2021001722A1 publication Critical patent/CL2021001722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente descripción proporciona compuestos de acuerdo con la Fórmula I, Fórmula II, y sus sales, tautómeros y/o isotopólogos farmacéuticamente aceptables como se describe en la descripción. Los compuestos son inhibidores de la isoforma 2A de la metionina adenosiltransferasa (MAT2A). También se proporcionan composiciones farmacéuticas y métodos para usar los compuestos para tratar cánceres, que incluyen algunos cánceres en los que se elimina el gen que codifica la metiltioadenosina fosforilasa (MTAP).
CL2021001722A 2018-12-27 2021-06-25 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer CL2021001722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862785574P 2018-12-27 2018-12-27

Publications (1)

Publication Number Publication Date
CL2021001722A1 true CL2021001722A1 (es) 2022-02-18

Family

ID=69400626

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001722A CL2021001722A1 (es) 2018-12-27 2021-06-25 Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer

Country Status (21)

Country Link
US (1) US20220098203A1 (es)
EP (1) EP3902804A1 (es)
JP (1) JP2022516882A (es)
KR (1) KR20220050832A (es)
CN (1) CN113474347A (es)
AR (1) AR115296A1 (es)
AU (1) AU2019414446A1 (es)
BR (1) BR112021012599A2 (es)
CA (1) CA3124678A1 (es)
CL (1) CL2021001722A1 (es)
CO (1) CO2021009882A2 (es)
CR (1) CR20210409A (es)
EA (1) EA202191800A1 (es)
IL (1) IL284324A (es)
JO (1) JOP20210171A1 (es)
MA (1) MA54609A (es)
MX (1) MX2021007833A (es)
PE (1) PE20212303A1 (es)
SG (1) SG11202106627WA (es)
TW (1) TW202039489A (es)
WO (1) WO2020139992A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
WO2021219731A2 (en) * 2020-04-28 2021-11-04 Iomx Therapeutics Ag Bicyclic kinase inhibitors and uses thereof
CN115960098A (zh) * 2020-09-11 2023-04-14 上海凌达生物医药有限公司 一类含氮稠环类化合物的制备方法和用途
CN116670144A (zh) * 2020-12-31 2023-08-29 南京再明医药有限公司 三环类化合物及用途
WO2022206730A1 (zh) * 2021-03-29 2022-10-06 武汉人福创新药物研发中心有限公司 嘧啶并吡嗪酮化合物及其用途
WO2023116696A1 (zh) * 2021-12-21 2023-06-29 南京正大天晴制药有限公司 蛋氨酸腺苷转移酶2a的杂环抑制剂
TW202333696A (zh) * 2022-01-26 2023-09-01 大陸商勤浩醫藥(蘇州)有限公司 用於治療ｍｔａｐ缺失型癌症的甲硫氨酸腺苷轉移酶２ａ抑制劑
TW202342024A (zh) * 2022-03-11 2023-11-01 大陸商賽諾哈勃藥業（成都）有限公司 甲硫胺酸腺苷轉移酶抑制劑、其藥物組合物及應用
GB202204913D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd antiviral therapy
WO2024080788A1 (ko) 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
CA2347474C (en) * 1998-10-23 2008-08-26 F. Hoffmann-La Roche Ag Bicyclic nitrogen heterocycles
BR0015243A (pt) * 1999-10-21 2002-07-16 Hoffmann La Roche Heterociclos de nitrogênio bicìclico substituìdos por heteroalquilamino como inibidores da proteìna cinase p38
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7129351B2 (en) * 2002-11-04 2006-10-31 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
CN100497339C (zh) * 2003-04-10 2009-06-10 霍夫曼-拉罗奇有限公司 嘧啶并化合物
US7897762B2 (en) * 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
JP5478488B2 (ja) 2007-06-20 2014-04-23 メルク・シャープ・アンド・ドーム・コーポレーション Ｊａｎｕｓキナーゼの阻害剤
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
SG11201901747VA (en) * 2016-08-31 2019-03-28 Agios Pharmaceuticals Inc Inhibitors of cellular metabolic processes
WO2019029541A1 (zh) * 2017-08-08 2019-02-14 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂及其用途
US11524960B2 (en) * 2018-03-30 2022-12-13 Servier Pharmaceuticals Llc Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer

Also Published As

Publication number Publication date
US20220098203A1 (en) 2022-03-31
CR20210409A (es) 2022-01-24
MA54609A (fr) 2022-04-06
TW202039489A (zh) 2020-11-01
KR20220050832A (ko) 2022-04-25
IL284324A (en) 2021-08-31
PE20212303A1 (es) 2021-12-10
SG11202106627WA (en) 2021-07-29
EP3902804A1 (en) 2021-11-03
JP2022516882A (ja) 2022-03-03
AU2019414446A1 (en) 2021-07-15
CO2021009882A2 (es) 2021-10-29
CN113474347A (zh) 2021-10-01
JOP20210171A1 (ar) 2023-01-30
WO2020139992A1 (en) 2020-07-02
BR112021012599A2 (pt) 2021-09-08
EA202191800A1 (ru) 2021-09-13
CA3124678A1 (en) 2020-07-02
MX2021007833A (es) 2021-10-26
AR115296A1 (es) 2020-12-16

Similar Documents

Publication Publication Date Title
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
CL2021001722A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
CL2021001721A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CO2021008895A2 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
ECSP22011692A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
PH12020552148A1 (en) Purinone compounds and their use in treating cancer
SV2018005655A (es) "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer"
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
ECSP21026485A (es) Piridazinonas y sus métodos de uso
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
UY39477A (es) Compuestos espiro heterocíclicos y métodos de uso
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
CL2023002633A1 (es) Derivados de uracilo como inhibidores de trpa1
CO2020013834A2 (es) Ciertos compuestos de pladienolida y métodos de uso
CO2021014351A2 (es) Derivados de quinolina y su uso para el tratamiento del cáncer
CL2022001777A1 (es) Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a
EA202092016A1 (ru) Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b
EA202190204A1 (ru) Производные конденсированных пиразинов как ингибиторы a2a/a2b
AR114282A1 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida (“tcd”)